AT1 FY21 - General Discussion + FA, page-1757

I was only thinking yesterday that if they don't take them up on the 2 mill devices and don't want to cough up the $$$ AT1 would be better pushing for the remaining contract value of the supply agreement in the form of free RAT devices from Access Bio to the same value. This would be a good boost to cash flow, especially when they know they now have the demand to sell these devices in Australia. In addition it would come with $0.00 manufacturing costs. So the Cost of Good Sold would be next to nothing for a whole bunch of antigen tests.

This solution might also help sweeten the relationship between AT1 and Access Bio, as it would be much better than trying to hold them to the contract that they don't need or want with the antibody tests from their end.